ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Regeneron Pharmaceuticals and Bayer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Regeneron PharmaceuticalsBayer
studies on the registry4131,694
open to participants now8360
phase 3 studies under way3811
reach primary completion within a year3035
programswith a study of their own in two years4321

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRegeneron PharmaceuticalsBayer
Phase 1

Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20934phase 1

and 3 more — sign in to see them all

19%
19%
Phase 2

Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

37%

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%
Phase 3

Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

35%

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%
Approved, new studies

Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Regeneron Pharmaceuticals

New programs 5

  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2 · Carcinoma, Renal Cell
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionRegeneron PharmaceuticalsBayer
Carcinoma, Non-Small-Cell Lungboth · compare here

Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3
  3. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Atrial Fibrillationboth · compare here

Regeneron Pharmaceuticals in Atrial Fibrillation: 2 programs

  1. cenvacibartphase 3
  2. amrecibartphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Atrial Fibrillation in search

Bayer in Atrial Fibrillation: 1 program

  1. BAY 3670549phase 2

Their studies: Bayer’s studies of Atrial Fibrillation in search

Coronary Artery Diseaseboth · compare here

Regeneron Pharmaceuticals in Coronary Artery Disease: 1 program

  1. alirocumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Coronary Artery Disease in search

Bayer in Coronary Artery Disease: 2 programs

  1. nurandociguatphase 2
  2. Aspirinapproved, new study

Their studies: Bayer’s studies of Coronary Artery Disease in search

Diabetes Mellitus, Type 2both · compare here

Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

Parkinson Diseaseboth · compare here

Regeneron Pharmaceuticals in Parkinson Disease: 1 program

  1. ALN-SNCAphase 1

Their studies: Regeneron Pharmaceuticals’ studies of Parkinson Disease in search

Bayer in Parkinson Disease: 2 programs

  1. bemdaneprocelphase 3
  2. AB-1005phase 2

Their studies: Bayer’s studies of Parkinson Disease in search

Prostatic Neoplasmsboth · compare here

Regeneron Pharmaceuticals in Prostatic Neoplasms: 2 programs

  1. olsutamigphase 2
  2. REGN21353phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Prostatic Neoplasms in search

Bayer in Prostatic Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Prostatic Neoplasms in search

Renal Insufficiency, Chronicboth · compare here

Regeneron Pharmaceuticals in Renal Insufficiency, Chronic: 1 program

  1. vonsetamigphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Renal Insufficiency, Chronic in search

Bayer in Renal Insufficiency, Chronic: 2 programs

  1. nurandociguatphase 2
  2. finerenoneapproved, new study

Their studies: Bayer’s studies of Renal Insufficiency, Chronic in search

Rhinitis, Allergicboth · compare here

Regeneron Pharmaceuticals in Rhinitis, Allergic: 2 programs

  1. bremzalerbartphase 3
  2. atisnolerbartphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Rhinitis, Allergic in search

Bayer in Rhinitis, Allergic: 1 program

  1. Oxymetazolinephase 2

Their studies: Bayer’s studies of Rhinitis, Allergic in search

Diabetic Nephropathiesboth · compare here

Regeneron Pharmaceuticals in Diabetic Nephropathies: 1 program

  1. ALN-ANG3phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Diabetic Nephropathies in search

Bayer in Diabetic Nephropathies: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Diabetic Nephropathies in search

Heart Failureboth · compare here

Regeneron Pharmaceuticals in Heart Failure: 1 program

  1. vixticibartphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Heart Failure in search

Bayer in Heart Failure: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Heart Failure in search

Neoplasm Metastasisboth · compare here

Regeneron Pharmaceuticals in Neoplasm Metastasis: 1 program

  1. cemiplimabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Neoplasm Metastasis in search

Bayer in Neoplasm Metastasis: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasm Metastasis in search

Neoplasmsboth · compare here

Regeneron Pharmaceuticals in Neoplasms: 1 program

  1. fianlimabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Neoplasms in search

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Regeneron Pharmaceuticals 17 of 43 · Bayer 13 of 21 programs (29 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.